Shares of GW Pharmaceuticals PLC- (NASDAQ:GWPH) dropped 1.6% during trading on Thursday . The stock traded as low as $81.20 and last traded at $81.20, with a volume of 114,511 shares trading hands. The stock had previously closed at $82.53.

GWPH has been the topic of several recent analyst reports. Cantor Fitzgerald started coverage on shares of GW Pharmaceuticals PLC- in a research report on Thursday, June 2nd. They set a “buy” rating and a $181.00 price objective on the stock. Morgan Stanley reiterated a “buy” rating and issued a $149.00 price target on shares of GW Pharmaceuticals PLC- in a report on Friday, June 10th. Vetr downgraded shares of GW Pharmaceuticals PLC- from a “strong-buy” rating to a “buy” rating and set a $87.65 price target on the stock. in a report on Monday, May 16th. Cowen and Company reiterated a “buy” rating and issued a $135.00 price target on shares of GW Pharmaceuticals PLC- in a report on Tuesday, August 9th. Finally, Zacks Investment Research upgraded shares of GW Pharmaceuticals PLC- from a “hold” rating to a “strong-buy” rating and set a $108.00 price target on the stock in a report on Tuesday, July 5th. Two analysts have rated the stock with a sell rating, one has assigned a hold rating, seven have given a buy rating and one has issued a strong buy rating to the company’s stock. GW Pharmaceuticals PLC- has an average rating of “Buy” and an average target price of $126.01.

The firm’s market cap is $1.79 billion. The firm has a 50 day moving average price of $90.87 and a 200-day moving average price of $78.07.

GW Pharmaceuticals PLC- (NASDAQ:GWPH) last released its quarterly earnings data on Tuesday, August 9th. The biopharmaceutical company reported ($0.06) EPS for the quarter, beating the consensus estimate of ($1.21) by $1.15. The business earned $3.10 million during the quarter, compared to analysts’ expectations of $3.63 million. During the same period last year, the company earned ($0.09) earnings per share. The firm’s revenue was down 73.3% on a year-over-year basis. Analysts anticipate that GW Pharmaceuticals PLC- will post ($4.52) earnings per share for the current year.

An institutional investor recently raised its position in GW Pharmaceuticals PLC- stock. Trexquant Investment LP boosted its position in GW Pharmaceuticals PLC- (NASDAQ:GWPH) by 188.9% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 23,719 shares of the biopharmaceutical company’s stock after buying an additional 15,509 shares during the period. Trexquant Investment LP owned approximately 0.11% of GW Pharmaceuticals PLC- worth $1,647,000 at the end of the most recent reporting period.

GW Pharmaceuticals plc is involved in the development of cannabinoid prescription medicines using botanical extracts derived from the Cannabis Sativa plant. The Company develops a portfolio of cannabinoid medicines, including Epidiolex, which is an oral medicine for the treatment of refractory childhood epilepsies.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.